基因重组白细胞介素-11治疗难治性特发性血小板减少性紫癜和再生障碍性贫血

Treatment of refractory idiopathic thrombocytopenic purpura and aplastic anemia with rIL-11

目的探讨基因重组白细胞介素-11(rhIL-11)治疗难治性特发性血小板减少性紫癜(RITP)和再生障碍性贫血(AA)的临床疗效。方法对48例RITP和8例AA患者进行rhIL-11治疗,剂量为1.5mg/d,肌肉注射,14d为1个疗程,间隔1周,再用1个疗程。RITP患者配合泼尼松应用,剂量0.5～1.0mg/(kg.d)口服。AA患者同时给予雄性激素及补血益气中药治疗。治疗期间进行外周血小板计数及相关参数、骨髓象等检测。结果随访6个月以上,48例RITP中基本治愈22例,显效16例,进步6例,无效4例,总有效率92%。8例AA中3例血小板升至100×109/L以上,5例血小板有所升高或减少血小板输入量。所有患者均能耐受治疗,未发生严重不良反应。结论rIL-11联合泼尼松治疗难治性ITP有良好的近期疗效。

[Objective] To determine the clinic effect of rhIL-11 for treatment of refractory idiopathic thrombocytopenic purpura （RITP） and aplastic anemia （AA）. [Methods] A total of 48 RITP and 8 AA patients had treated with rhIL-11, 22 patients had treated with rhIL-11 only, 26 patients had treated with rhIL-11 and Prednisone. rhIL-11 was given at a dose of 1.5 mg/d for 28 d, and Prednisone was given at a dose of （0.5-1.0） mg/kg body weight per day. 8 AA patients had treated with rhIL-11 and another treatment. [Results] Showed that in 44 cases acquired effectiveness in RITP, of whom, 22 cases achieved curative effective, 16 achieved significant effectiveness, and 6 effective. 4 patients did not acquire effectiveness. There were no serious side effects associated during the treatment. [Conclusion] rhIL-11 is effective and safe for treatment of RITP and AA.